2006
DOI: 10.1007/s10482-005-9037-7
|View full text |Cite
|
Sign up to set email alerts
|

Evaluation of the usefulness of anti-glyceraldehyde-3-phosphate dehydrogenase antibodies as a treatment for invasive candidiasis in a murine model

Abstract: We have evaluated the effect of antibodies against the Candida albicans glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as a potential immunotherapeutic treatment for acute invasive candidiasis in a murine model of infection. Three different approaches were assayed: (i) active immunization of mice using recombinant His-tagged GAPDH, (ii) treatment of fungal yeast cells with anti-GAPDH antibodies prior to infection, and (iii) passive transfer of polyclonal anti-GAPDH antibodies. Results showed that all three a… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

1
10
0

Year Published

2008
2008
2024
2024

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 12 publications
(11 citation statements)
references
References 22 publications
1
10
0
Order By: Relevance
“…The Poor Prognosis-Associated, Risk Antibodies in the ICPS are Directed to Potential Candida Proapoptotic Mediators-Although the mechanisms by which antibodies to Gap1p/Tdh3p and Ssb1p may negatively affect the clinical outcome of IC patients are unclear, earlier studies strengthen our results (62,63,65,87). Passive transfer and immunization assays in animal models have shown that anti-Gap1p/Tdh3p antibodies are neither protective nor can they stimulate protective responses against IC (62,63).…”
Section: The Biologic Relevance Of the Antibodies Included In The Icpsupporting
confidence: 64%
See 2 more Smart Citations
“…The Poor Prognosis-Associated, Risk Antibodies in the ICPS are Directed to Potential Candida Proapoptotic Mediators-Although the mechanisms by which antibodies to Gap1p/Tdh3p and Ssb1p may negatively affect the clinical outcome of IC patients are unclear, earlier studies strengthen our results (62,63,65,87). Passive transfer and immunization assays in animal models have shown that anti-Gap1p/Tdh3p antibodies are neither protective nor can they stimulate protective responses against IC (62,63).…”
Section: The Biologic Relevance Of the Antibodies Included In The Icpsupporting
confidence: 64%
“…In addition to the five recombinant C. albicans protein dots, each immunoarray included negative (C-; bovine serum albumin) and positive (Cϩ; C. albicans protein extract) control dots to monitor experimental performance. Numbers above each pattern indicate tective antibodies, such as those to Hsp90p, Eno1p, Met6p, or Fba1p (13, 15, 56 -62), whereas the poor-prognosis signature was associated with undetectable/lower levels of them (possibly insufficient to induce protection (55)) and higher levels of nonprotective antibodies, like those to Gap1p/Tdh3p (62,63) or Ssa4p, Ssb1p or Ssc1p (cell wall-exposed, Hsp70p family members (42,64)). The latter is gathered from the nonprotective effect of anti-surface Hsp70p antibodies (65) and their high homology degree (see below).…”
Section: Fig 9 Prognostic Performance Of the Multiplexed Immunoassamentioning
confidence: 99%
See 1 more Smart Citation
“…Vesicle transportation could explain the reason by which some nuclear and cytosol proteins are detected in cell wall and culture medium. For instance, proteins such as enolase (Karkowska‐Kuleta et al ., ), glyceraldehyde‐3‐phosphate dehydrogenase (Gpdh) (Gil et al ., ), fructose‐bisphosphate aldolase (Pitarch et al ., ), triosephosphate isomerase (Tpi), phosphoglycerate kinase (Pgk) (Karkowska‐Kuleta et al ., ) and phosphoglycerate mutase (Crowe et al ., ; Karkowska‐Kuleta et al ., ) all play key roles in the glycolytic pathway and are detected at the C. albicans cell wall. Notably, enolase, Gpdh, Tpi, Pgk and the glycosyl hydrolase Bgl2, all components of C. albicans EV, elicit human antibodies in systemic candidiasis (Pitarch et al ., ).…”
Section: Discussionmentioning
confidence: 99%
“…However, a study on its potential immunotherapeutic use showed that antibodies against Gap1p did not confer protection in murine model of systemic candidiasis (Gil et al . ).…”
Section: Discussionmentioning
confidence: 97%